Completed OBSERVATIONAL NCT03651635

MR-proADM and CT-proET-1 During ICU Treatment (MR-proADM)

To Assess and Validate the Use of MR-proADM and the CT-proET-1/MR-proADM Ratio as Prognostic Markers During the First 7 Days of ICU Treat-ment

Sponsor: ThermoFisher Scientific Brahms Biomarkers France

Conditions Acute Phase Biomarkers Medical ICU Admitted Patients

Interventions Blood sampling for MR-proADM & CT-proET-1

Updated 8 times since 2018 Last updated: May 27, 2021 Started: Jan 8, 2018 Primary completion: Feb 28, 2019 Completion: Feb 28, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03651635, this observational or N/A phase trial focuses on Acute Phase Biomarkers and Medical ICU Admitted Patients and remains completed. Sponsored by ThermoFisher Scientific Brahms Biomarkers France, it has been updated 8 times since 2018, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Dec 2021 — Jul 2024 [monthly]

Completed
Sep 2021 — Dec 2021 [monthly]

Completed

Status: Unknown Status → Completed
Jan 2021 — Sep 2021 [monthly]

Unknown Status

▶ Show 3 earlier versions

Nov 2020 — Jan 2021 [monthly]

Unknown Status
Sep 2020 — Nov 2020 [monthly]

Unknown Status

Status: Recruiting → Unknown Status
Sep 2018 — Sep 2020 [monthly]

Recruiting

First recorded

Jan 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

ThermoFisher Scientific Brahms Biomarkers France
University of Zurich

Data source: University of Zurich

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Zurich, Switzerland